MedTrace Logo

Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

NCT05016050 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 367

Last updated 2023-06-01

No results posted yet for this study

Summary

Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time. After the treatment period, participants will be followed monthly for 12 months.

Conditions

Interventions

DEVICE

HPDT-DA-013

Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).

Sponsors & Collaborators

  • Happify Inc.

    lead INDUSTRY

Principal Investigators

  • Roger Vilardaga, Ph.D. · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2023-03-16
Completion
2023-04-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05016050 on ClinicalTrials.gov